Danish cancer antibody powerhouse Genmab plans to raise US$505m in its US IPO. The money will go towards its...
Up To Date
Latest News
Dutch biopharma company AM-Pharma B.V. has secured €116m to bring its acute kidney injury treatment into Phase...
Belgian biotech Galapagos NV has entered into a R&D collaboration with Gilead Sciences. The US drug maker is...
German pharma major Boehringer Ingelheim has taken over Swiss cancer immunotherapy player AMAL Therapeutics.
French microalgae specialist Microphyt has raised €28.5m to develop its microalgae portfolio for nutrition and...
French biotech Osivax has raised €8m to fast-track development of its lead flu vaccine candidate – and branch...